Cargando…

GOF Mutant p53 in Cancers: A Therapeutic Challenge

SIMPLE SUMMARY: In normal cells, p53 is a protein which regulates the cell cycle progression to ensure normal cell division, growth, and development. However, in cancer, changes in the p53 DNA sequence, called genetic mutation, results in the protein either losing its normal function or exhibiting a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dolma, Lobsang, Muller, Patricia A. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600758/ https://www.ncbi.nlm.nih.gov/pubmed/36291874 http://dx.doi.org/10.3390/cancers14205091

Ejemplares similares

Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches
por: Roszkowska, Katarzyna A., et al.
Publicado: (2022)

Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
por: Schulz-Heddergott, Ramona, et al.
Publicado: (2018)

A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis
por: Yue, Xuetian, et al.
Publicado: (2016)

Depleting stabilized GOF mutant p53 proteins by inhibiting molecular folding chaperones: a new promise in cancer therapy
por: Alexandrova, Evguenia M, et al.
Publicado: (2017)

Transcriptome profiling identifies genes and pathways deregulated upon floxuridine treatment in colorectal cancer cells harboring GOF mutant p53
por: Datta, Arindam, et al.
Publicado: (2016)

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
por: Muller, Patricia A.J., et al.
Publicado: (2014)

The Irrationality of GOF Avian Influenza Virus Research
por: Wain-Hobson, Simon
Publicado: (2014)

Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter
por: Vaughan, Catherine A., et al.
Publicado: (2016)

NLRC4 GOF Mutations, a Challenging Diagnosis from Neonatal Age to Adulthood
por: Bardet, Juliette, et al.
Publicado: (2021)

p53 and its mutants in tumor cell migration and invasion
por: Muller, Patricia A. J., et al.
Publicado: (2011)

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
por: Zhang, Shengliang, et al.
Publicado: (2022)

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
por: Chen, Xiaohua, et al.
Publicado: (2022)

Ruxolitinib Controls Lymphoproliferation and Diabetes in a STAT3-GOF Patient
por: Wegehaupt, Oliver, et al.
Publicado: (2020)

The Diverse Functions of Mutant 53, Its Family Members and Isoforms in Cancer
por: Hall, Callum, et al.
Publicado: (2019)

Zinc Metallochaperones as Mutant p53 Reactivators: A New Paradigm in Cancer Therapeutics
por: Kogan, Samuel, et al.
Publicado: (2018)

Mutant p53 in colon cancer
por: Nakayama, Mizuho, et al.
Publicado: (2018)

New therapeutic strategies to treat human cancers expressing mutant p53 proteins
por: Blandino, Giovanni, et al.
Publicado: (2018)

Mutant p53 as an Antigen in Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2020)

p53’s Extended Reach: The Mutant p53 Secretome
por: Pavlakis, Evangelos, et al.
Publicado: (2020)

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
por: Na, Bing, et al.
Publicado: (2019)

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient
por: Thalhammer, Julian, et al.
Publicado: (2021)

Treating p53 Mutant Aggregation-Associated Cancer
por: Kanapathipillai, Mathumai
Publicado: (2018)

Mutant p53 as a guardian of the cancer cell
por: Mantovani, Fiamma, et al.
Publicado: (2018)

Mutant p53 partners in crime
por: Kim, Michael P, et al.
Publicado: (2018)

Editorial: Mutant p53 in Cancer Progression and Personalized Therapeutic Treatments
por: Timofeev, Oleg
Publicado: (2021)

Statistical power estimation dataset for external validation GoF tests on EVT distribution
por: Reghenzani, Federico, et al.
Publicado: (2019)

Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF Patients
por: Bloomfield, Marketa, et al.
Publicado: (2021)

p53 tetramerization: at the center of the dominant-negative effect of mutant p53
por: Gencel-Augusto, Jovanka, et al.
Publicado: (2020)

Mutant p53 in cell-cell interactions
por: Pilley, Steven, et al.
Publicado: (2021)

Mutant p53 in cancer therapy—the barrier or the path
por: Zhou, Xiang, et al.
Publicado: (2018)

Complexes formed by mutant p53 and their roles in breast cancer
por: Bellazzo, Arianna, et al.
Publicado: (2018)

Gain-of-function mutant p53 in cancer progression and therapy
por: Zhang, Cen, et al.
Publicado: (2020)

The Function of the Mutant p53-R175H in Cancer
por: Chiang, Yen-Ting, et al.
Publicado: (2021)

Cancer therapeutic targeting using mutant–p53-specific siRNAs
por: Ubby, Ifeoma, et al.
Publicado: (2019)

Goiter in Tibetan Medicine
por: Burrow, Gerard N., et al.
Publicado: (1978)

Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC
por: Zhang, Yaqun, et al.
Publicado: (2019)

Vagueness and Costs of the Pause on Gain-of-Function (GOF) Experiments on Pathogens with Pandemic Potential, Including Influenza Virus
por: Imperiale, Michael J., et al.
Publicado: (2014)

Genomic instability in mutant p53 cancer cells upon entotic engulfment
por: Mackay, Hannah L., et al.
Publicado: (2018)

The rebel angel: mutant p53 as the driving oncogene in breast cancer
por: Walerych, Dawid, et al.
Publicado: (2012)

The aggregation of mutant p53 produces prion-like properties in cancer
por: Rangel, Luciana P, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_oll1qbo6j7m5ct8mp4f78lk1t2